Medicaid Gives New Protections to Beneficiaries in Managed Care Plans

Latin American patients appear more likely to be diagnosed with aggressive early-stage breast cancer based on factors including metabolics and genetics, according to findings from the FLEX study.

Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

Investigators observe no new safety signals with trastuzumab emtansine as a treatment for HER2-positive breast cancer after 8 years of follow-up in the phase 3 KATHERINE study.

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

Future research may focus on the relationship between neoadjuvant chemotherapy regimens, pathologic complete response, and whole transcriptome changes in patients with hormone receptor–positive, HER2-negative early-stage breast cancer.

Quality of life also appears to be maintained with elacestrant in estrogen receptor–positive or HER2-negative ESR1-mutated breast cancer in the phase 3 EMERALD trial.